Eli Lilly’s 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release over one to six months, but conveyed no commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Traders assign an 87.5% implied probability to “No” because the absence of any announced commercial terms, combined with the competitor partnership and the short window remaining before the October 7 resolution date, signals limited near-term momentum for a full license.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% tsansa
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% tsansa
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release over one to six months, but conveyed no commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Traders assign an 87.5% implied probability to “No” because the absence of any announced commercial terms, combined with the competitor partnership and the short window remaining before the October 7 resolution date, signals limited near-term momentum for a full license.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Binuksan ang Market: May 5, 2026, 8:02 PM ET
Volume
$11,264Petsa ng Pagtatapos
Oct 7, 2026Binuksan ang Market
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release over one to six months, but conveyed no commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Traders assign an 87.5% implied probability to “No” because the absence of any announced commercial terms, combined with the competitor partnership and the short window remaining before the October 7 resolution date, signals limited near-term momentum for a full license.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264Petsa ng Pagtatapos
Oct 7, 2026Binuksan ang Market
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release over one to six months, but conveyed no commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Traders assign an 87.5% implied probability to “No” because the absence of any announced commercial terms, combined with the competitor partnership and the short window remaining before the October 7 resolution date, signals limited near-term momentum for a full license.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong